Fritextsökning
Artiklar per år
Innehållstyper
-
We are poor lobbyists
I doubt there has ever been a really well thought out Scandinavian campaign with intentions to really change attitudes among both the public and politicians.
-
De värsta spökskrivarna i läkemedelshistorien
Tre av de värsta fallen listas där stora läkemedelsföretag använder spökskrivare för att promota sina läkemedel.
-
75 million for research schools
Gothenburg University, Karolinska Institutet, Linköping University and Umeå University have received SEK 75 million from the Research Council. The money will be used to build five national clinical research schools. The research schools will receive 15
-
VTT in brief
VTT is a broad science cluster with research within applied materials, chemical and biochemical processes, energy, industrial systems management, information and communication technologies, microtechnology and electronics.
-
BMAs: Run your own business
After graduation you must decide: be an employee or start your own business. This is not really the situation for BMAs today, but a collaborative project between Swedish public actors and some companies aims to change that and make entrepreneurs of BMAs.
-
A crash course in IP strategy
"Publish, publish, publish!" Sound familiar? So to meet the researcher's wishes, do you scribble a patent application with lipstick on a napkin and send it in? At the seminar Patent Strategies in the Biotech Company, you will have the chance to find out why this might not be the best idea.
-
Enjoy Stockholm - the capital of Scandinavia
Welcome to Stockholm! Built on 14 islands, you are never far from the water in the capital of Sweden. Stockholm offers a wide range of museums, theaters, and attractions. Whatever your interest might be: history, art, music or design, you can find it here!
-
The winner of the race
She learned how to work hard at an early age and her devotion has certainly paid off. Whether it is field running or running a company, the key to success is focus according to Yvonne Mårtensson.
-
Faster sales but less profits for Probi
The probiotic company increases its turnover, and the net results are twice as large as last year.
-
Go ahead for leg wound study
Tripep starts a phase II-study of their wound healing joint venture project.
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
Grant for development projects in Gothenburg
Seven research projects receive SEK 1 million to promote commercialization of early drug development and medical technology.
-
New CEO to Promedvi
Sigrun Axelsson has taken on the leadership of the Lund-based medtech company.
-
EUR 2 million for peanut allergies
ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.
-
Fusion between pharma giants?
It is rumoured that a fusion between Pfizer and Wyeth is in the process of happening.
-
Less scars with new product
A new Swedish product for post surgical scar formation enters clinical development.
-
Lytix calls in cash
Norwegian company Lytix Biopharma closes a USD 1.4 million funding round to finance new antimicrobial and oncology lead compounds.
-
Vattenfall is firing with biomass
Vattenfall will provide Denmark with electricity by means of biomass.
-
Hormones make children fat
A new Danish million project will define the connection between hormons and obesity amongst children.
-
Respiratorius hunts millions
The biopharmaceutical company Respiratorius has got a new CEO, who starts a public new share issue to catch almost SEK ten million.
-
Future drugs from Amaryllis
A Danish research team has discovered possibolities to extract drugs fro Amaryllis.
-
Eli Lilly writes biotech fine history
The American biotech company Eli Lilly will pay US 1.415 billion to resolve allegations of off-label promotion of a dementia drug.
-
New NO product reduces diabetic pain
The Swedish medtech company Nolabs has announced that it has achieved an important milestone in the development of a new line of products.